Health Care·Pharmaceuticals·$277.6B
Novartis AG is a global healthcare company focused on developing and manufacturing innovative pharmaceuticals. With a market cap of $282 billion, it plays a crucial role in the healthcare sector, addressing various medical needs and advancing treatments for serious diseases.
Earnings Per Share (EPS)
EPS is a key indicator of the company's profitability and performance. Investors will be watching closely to see if Novartis can meet or exceed the consensus estimate.
Revenue
Revenue figures provide insight into the company's sales performance and market demand for its products. A strong revenue report could signal growth and stability.
Wall Street expectations, options signals, track record, and call prep available with Pro.
Novartis AG is a global healthcare company focused on developing and manufacturing innovative pharmaceuticals. With a market cap of $282 billion, it plays a crucial role in the healthcare sector, addressing various medical needs and advancing treatments for serious diseases.
EPS Beat Streak
1Q
EPS Beat Rate
88%
Avg EPS Surprise
+4.84%
Avg Stock Reaction
-1.40%
In the last quarter, Novartis reported an EPS of $2.03, exceeding expectations by 2.11%. The company continues to show resilience in a competitive pharmaceutical market.
Management Promises & Guidance
Analysts expect Novartis to report solid earnings this quarter, with a consensus EPS of $2.07 and revenue of $13.5 billion. The market is keen to see if the company can maintain its growth trajectory.
Bull Case
If Novartis beats the EPS estimate and shows strong revenue growth, it could reinforce investor confidence and drive the stock price higher.
Bear Case
Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a decline in stock price as investors reassess the company's outlook.
Earnings Per Share (EPS)
$2.07EPS is a key indicator of the company's profitability and performance. Investors will be watching closely to see if Novartis can meet or exceed the consensus estimate.
Revenue
$13.5BRevenue figures provide insight into the company's sales performance and market demand for its products. A strong revenue report could signal growth and stability.
The print will turn on these two things.
Q1
Will Novartis achieve an EPS of at least $2.07?
This figure is crucial as it reflects the company's profitability and could influence investor sentiment significantly.
Q2
What will the revenue figure be, and how does it compare to the $13.5 billion consensus?
Revenue performance is a key indicator of market demand and the company's ability to grow, impacting future guidance and stock performance.
Why consensus could be wrong
The Street may be underestimating Novartis's potential for revenue growth, particularly in key therapeutic areas where recent product launches have gained traction.
Supporting Evidence
The company has a history of exceeding EPS estimates, suggesting it may outperform again this quarter.
Options pricing indicates a significant expected move, reflecting uncertainty that could lead to a surprise in either direction.
Key Risk
If revenue comes in significantly above $13.5 billion, it could challenge the current consensus and shift investor sentiment positively.
Pre-commit to what would confirm each case.
The market is debating whether Novartis can sustain its growth amidst competitive pressures and evolving market conditions.
Bull Confirmed If
An EPS of $2.10 or higher would confirm the bull case, indicating strong operational performance.
Bear Confirmed If
An EPS below $2.00 would support the bear case, suggesting potential issues in profitability.
Implied Move
±5%
Historical Avg
±2.7%
The options market is pricing in a potential move of 5% in either direction following the earnings report, indicating uncertainty among investors.
Options are pricing ±5.0% while NVS has averaged ±2.7% over the last 8 prints — setup is pricing rich.
Cross-company pattern from 30 similar setups.
Prior-quarter beat setup in Health Care
n=30Fade rate: 16 of 29 (55%)
This setup has occurred 30 times across Health Care in the last 2 years. 16 of 29 faded and 13 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 4.1%, with a raw directional average of -0.7% (modestly negative historical bias).
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Novartis beats expectations, history suggests the stock could rise by an average of 4.1% on the day, confirming a positive outlook.
In-Line / Cautious
If results are in line with expectations, the market may react cautiously, leading to muted stock movement as investors digest the commentary.
Miss
If the company misses expectations, history suggests a potential decline of around 0.7% on the day, as investors reassess the company's growth prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
VERIZON COMMUNICATIO
Apr 27, 2026